Maarten J Ijzerman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/377253/publications.pdf

Version: 2024-02-01

310 papers

11,208 citations

51 h-index 93 g-index

316 all docs

316 does citations

316 times ranked

12293 citing authors

#	Article	IF	Citations
1	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology, 2023, 62, SI170-SI180.	1.9	4
2	Costs of <scp>Hospitalâ€Associated</scp> Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Arthritis Care and Research, 2022, 74, 1585-1592.	3.4	3
3	Heterogeneity in how women value risk-stratified breast screening. Genetics in Medicine, 2022, 24, 146-156.	2.4	8
4	Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation. European Radiology, 2022, 32, 3067-3075.	4.5	11
5	Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer, 2022, 166, 27-39.	2.0	4
6	Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. BMC Medical Research Methodology, 2022, 22, 83.	3.1	4
7	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient, 2022, 15, 599-609.	2.7	3
8	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology, 2022, 108, 469-485.	2.2	4
9	Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. BMC Cancer, 2022, 22, 283.	2.6	2
10	Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors. Supportive Care in Cancer, 2022, 30, 5299-5309.	2.2	5
11	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 2022, 20, 25.	2.1	8
12	Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. Value in Health, 2022, 25, 1063-1080.	0.3	24
13	Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 975-984.	1.4	8
14	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus, 2021, 7, 752-763.	3.1	9
15	Evaluating the resource implications of different service delivery models for offering additional genomic findings. Genetics in Medicine, 2021, 23, 606-613.	2.4	5
16	Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening. Value in Health, 2021, 24, 206-215.	0.3	4
17	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics, 2021, 11, 103.	2.6	33
18	Health Economic Evidence of Point-of-Care Testing: A Systematic Review. PharmacoEconomics - Open, 2021, 5, 157-173.	1.8	16

#	Article	IF	CITATIONS
19	An inverse stageâ€shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVIDâ€19 pandemic. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 359-367.	1.1	59
20	A scoping review of studies using observational data to optimise dynamic treatment regimens. BMC Medical Research Methodology, 2021, 21, 39.	3.1	13
21	Real-World Utilization of Biomarker Testing for Patients with Advanced Non–Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals. Journal of Molecular Diagnostics, 2021, 23, 484-494.	2.8	12
22	Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy. Medical Decision Making, 2021, 41, 693-705.	2.4	0
23	Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. BMC Health Services Research, 2021, 21, 513.	2.2	5
24	Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. European Urology Open Science, 2021, 27, 77-87.	0.4	1
25	Early technology assessment of using whole genome sequencing in personalized oncology. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 343-351.	1.4	4
26	Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer, 2021, 21, 488.	2.6	8
27	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics, 2021, 39, 953-964.	3.3	14
28	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. Value in Health, 2021, 24, 1737-1745.	0.3	4
29	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and Therapy, 2021, 8, 1303-1322.	2.3	6
30	Cost of colorectal cancer care: sufficient to inform cancer policy?. The Lancet Gastroenterology and Hepatology, 2021, 6, 679-680.	8.1	1
31	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. Value in Health, 2021, 25, 104-115.	0.3	2
32	How to Realize the Benefits of Point-of-Care Testing at the General Practice: A Comparison of Four High-Income Countries. International Journal of Health Policy and Management, 2021, , .	0.9	4
33	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. International Journal of Environmental Research and Public Health, 2021, 18, 13345.	2.6	11
34	Genomic Health Literacy Interventions in Pediatrics: Scoping Review. Journal of Medical Internet Research, 2021, 23, e26684.	4.3	4
35	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics, 2020, 38, 1263-1275.	3.3	3
36	Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process. Medical Decision Making, 2020, 40, 348-363.	2.4	8

#	Article	IF	CITATIONS
37	The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Cancers, 2020, 12, 1120.	3.7	6
38	Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value in Health, 2020, 23, 566-573.	0.3	32
39	Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer. Oncologist, 2020, 25, e1330-e1338.	3.7	6
40	Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?. Pharmacoeconomics, 2020, 38, 913-926.	3.3	4
41	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer, 2020, 146, 310-317.	2.0	46
42	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health, 2020, 23, 529-539.	0.3	59
43	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. Pharmacoeconomics, 2020, 38, 683-713.	3.3	10
44	Do assumptions in health economic evaluations hamper drug uptake?. Journal of Clinical Oncology, 2020, 38, e19289-e19289.	1.6	0
45	Pointâ€ofâ€care testing in primary care: A systematic review on implementation aspects addressed in test evaluations. International Journal of Clinical Practice, 2019, 73, e13392.	1.7	36
46	A scoping review of metamodeling applications and opportunities for advanced health economic analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 181-187.	1.4	10
47	Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands. Lung Cancer, 2019, 134, 34-41.	2.0	13
48	Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discovery Today, 2019, 24, 1720-1724.	6.4	105
49	Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatric Rheumatology, 2019, 17, 20.	2.1	10
50	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. Medical Decision Making, 2019, 39, 57-73.	2.4	10
51	Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography. Journal of Thoracic Imaging, 2019, 34, 160-169.	1.5	34
52	Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. Breast Cancer Research and Treatment, 2019, 175, 451-458.	2.5	14
53	PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS. Value in Health, 2019, 22, S632.	0.3	1
54	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health, 2019, 22, 13-20.	0.3	76

#	Article	IF	Citations
55	Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis. BMC Family Practice, 2019, 20, 8.	2.9	21
56	Answering real-world questions using real-world data: Understanding dynamic treatment decisions and outcomes in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2019, 37, e18061-e18061.	1.6	1
57	Assessing the cost-effectiveness of a routine versus an extensive laboratory work-up in the diagnosis of anaemia in Dutch general practice. Annals of Clinical Biochemistry, 2018, 55, 630-638.	1.6	9
58	Individual Value Clarification Methods Based on Conjoint Analysis: A Systematic Review of Common Practice in Task Design, Statistical Analysis, and Presentation of Results. Medical Decision Making, 2018, 38, 746-755.	2.4	11
59	The effectiveness of a routine versus an extensive laboratory analysis in the diagnosis of anaemia in general practice. Annals of Clinical Biochemistry, 2018, 55, 535-542.	1.6	9
60	Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non–ST elevation myocardial infarction patients. Journal of Evaluation in Clinical Practice, 2018, 24, 31-41.	1.8	15
61	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	3.1	14
62	Reasons for (not) discontinuing antipsychotics in dementia. Psychogeriatrics, 2018, 18, 13-20.	1.2	7
63	The Impact Of Cluster Selection Methods In Two-Stage Bootstrapping To Assess Uncertainty In Health Economic Outcomes In Cluster Randomized Controlled Trials. Value in Health, 2018, 21, S228.	0.3	0
64	Quality of Life of Adults with a History of Juvenile Idiopathic Arthritis: A Systematic Review. Value in Health, 2018, 21, S226.	0.3	O
65	Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands. Critical Care, 2018, 22, 293.	5.8	21
66	Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. Value in Health, 2018, 21, 1269-1277.	0.3	6
67	How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 1202-1206.	1.5	34
68	Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist. Medical Decision Making, 2018, 38, 778-788.	2.4	6
69	Women's preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment. Patient Preference and Adherence, 2018, Volume 12, 1837-1852.	1.8	13
70	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiology, 2018, 57, 60-67.	1.9	18
71	Riskâ€based breast cancer followâ€up stratified by age. Cancer Medicine, 2018, 7, 5291-5298.	2.8	9
72	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2018, 21, 1019-1028.	0.3	36

#	Article	IF	CITATIONS
73	Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis. American Journal of Cardiovascular Drugs, 2018, 18, 493-502.	2.2	14
74	Perceived advantages and disadvantages of oral anticoagulants, and the trade-offs patients make in choosing anticoagulant therapy and adhering to their drug regimen. Patient Education and Counseling, 2018, 101, 1982-1989.	2.2	18
75	Health economic impact of liquid biopsies in cancer management. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 593-599.	1.4	31
76	Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Medical Decision Making, 2018, 38, 822-833.	2.4	31
77	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	5.4	28
78	Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention, 2018, 14, e1049-e1056.	3.2	34
79	Consensus statement on circulating biomarkers for advanced prostate cancer Journal of Clinical Oncology, 2018, 36, 299-299.	1.6	1
80	Supporting the Project Portfolio Selection Decision of Research and Development Investments by Means of Multi-Criteria Resource Allocation Modelling. , 2017, , 89-103.		7
81	Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis. Pharmacoeconomics, 2017, 35, 259-269.	3.3	12
82	Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. Pharmacoeconomics, 2017, 35, 727-740.	3.3	116
83	Pharmacological and non-pharmacological treatment preferences of healthcare professionals and proxies for challenging behaviors in patients with dementia. International Psychogeriatrics, 2017, 29, 1377-1389.	1.0	10
84	Patient and Public Preferences for Treatment Attributes in Parkinson's Disease. Patient, 2017, 10, 763-772.	2.7	4
85	Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise. Value in Health, 2017, 20, 1336-1344.	0.3	12
86	Painful Discrimination in the Emergency Department: Risk Factors for Underassessment of Patients' Pain by Nurses. Journal of Emergency Nursing, 2017, 43, 228-238.	1.0	24
87	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2017, 20, 310-319.	0.3	79
88	Psychotropic Drug-Related Fall Incidents in Nursing Home Residents Living in the Eastern Part of The Netherlands. Drugs in R and D, 2017, 17, 321-328.	2.2	18
89	A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 17-25.	1.4	25
90	Determinants of the nurses' and nursing assistants' request for antipsychotics for people with dementia. International Psychogeriatrics, 2017, 29, 475-484.	1.0	19

#	Article	IF	CITATIONS
91	A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS. International Journal of Technology Assessment in Health Care, 2017, 33, 444-453.	0.5	1
92	Post-Up Study: Postpartum Depression Screening in Well-Child Care and Maternal Outcomes. Pediatrics, 2017, 140, .	2.1	20
93	Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care, 2017, 40, 1111-1120.	8.6	92
94	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2017, 20, 1411-1419.	0.3	7
95	Public Preferences for Lung Cancer Screening Policies. Value in Health, 2017, 20, 961-968.	0.3	10
96	Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes. Journal of Cardiology, 2017, 69, 660-665.	1.9	25
97	Screening for Postpartum Depression in Well-Baby Care Settings: A Systematic Review. Maternal and Child Health Journal, 2017, 21, 9-20.	1.5	35
98	Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 2950-2959.	2.7	31
99	A Qualitative Exploration of Reasons for (NON-) Adherence to Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Value in Health, 2017, 20, A620.	0.3	2
100	Estimating The Drug Treatment Cost of Breast Cancer. Value in Health, 2017, 20, A430-A431.	0.3	1
101	From Evaluation To Optimization: Using A Meta-Model To Maximize The Benefits Of Colorectal Screening Accounting For Capacity Constraints. Value in Health, 2017, 20, A757.	0.3	O
102	The cost of expensive breast cancer drugs. Annals of Oncology, 2017, 28, v398-v399.	1.2	O
103	Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. International Journal of Molecular Sciences, 2017, 18, 363.	4.1	39
104	Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences. PLoS ONE, 2017, 12, e0189251.	2.5	4
105	The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care. BMC Cardiovascular Disorders, 2017, 17, 213.	1.7	20
106	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Medical Research Methodology, 2017, 17, 170.	3.1	19
107	Improving early exclusion of acute coronary syndrome in primary care: the added value of point-of-care troponin as stated by general practitioners. Primary Health Care Research and Development, 2017, 18, 386-397.	1.2	6
108	Toward Patient-Centered Telerehabilitation Design: Understanding Chronic Pain Patients' Preferences for Web-Based Exercise Telerehabilitation Using a Discrete Choice Experiment. Journal of Medical Internet Research, 2017, 19, e26.	4.3	64

#	Article	IF	CITATIONS
109	Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments. Ecancermedicalscience, 2017, 11, ed71.	1.1	4
110	International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology, 2016, 34, 2936-2937.	1.6	12
111	A Review on the Current Status of Health Economic Modeling in Personalized Medicine. Value in Health, 2016, 19, A377.	0.3	O
112	Physicians' Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer. Value in Health, 2016, 19, A765-A766.	0.3	0
113	TCT-170 Clinical Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From DUTCH PEERS (TWENTE II) Randomized Trial. Journal of the American College of Cardiology, 2016, 68, B70.	2.8	O
114	Reflecting Uncertainty in Early HTA When Evidence on Parameter Distributions is Lacking: A Comparison of Methods. Value in Health, 2016, 19, A382.	0.3	0
115	An a Priori Decision Criteria Elicitation Method for Treatment Decision-Making in Elderly Colorectal Cancer Patients. Value in Health, 2016, 19, A392.	0.3	O
116	The Value of Mcda in Health Technology Assessment: A Explorative Study in the Dutch Context. Value in Health, 2016, 19, A469-A470.	0.3	0
117	Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents. American Heart Journal, 2016, 175, 121-129.	2.7	39
118	Disfunción endotelial tras infarto de miocardio con elevación del segmento ST y evolución a largo plazo: un estudio con tonometrÃa arterial periférica e hiperemia reactiva. Revista Espanola De Cardiologia, 2016, 69, 664-671.	1.2	4
119	Endothelial Dysfunction After ST-segment Elevation Myocardial Infarction and Long-term Outcome: A Study With Reactive Hyperemia Peripheral Artery Tonometry. Revista Espanola De Cardiologia (English) Tj ETQq1 I	l 0. 78431	46rgBT/Ove
120	Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales. Value in Health, 2016, 19, 226-232.	0.3	18
121	A nurse-initiated pain protocol in the ED improves pain treatment in patients with acute musculoskeletal pain. International Emergency Nursing, 2016, 27, 3-10.	1.5	29
122	Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial. Revista Espanola De Cardiologia (English) Tj ETQq(ായ െ rgBT	© verlock 1
123	Commercial viability of medical devices using Headroom and return on investment calculation. Technological Forecasting and Social Change, 2016, 112, 338-346.	11.6	18
124	Procalcitonin to guide antibiotic stewardship in intensive care. Lancet Infectious Diseases, The, 2016, 16, 888.	9.1	0
125	Psychotropic drug prescriptions in Western European nursing homes. International Psychogeriatrics, 2016, 28, 1775-1790.	1.0	86
126	Translational Health Economics. , 2016, , 405-440.		6

#	Article	IF	CITATIONS
127	Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 435-437.	1.4	25
128	Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 2016, 19, 300-315.	0.3	782
129	An Empirical Comparison of Discrete Choice Experiment and Best-Worst Scaling to Estimate Stakeholders' Risk Tolerance for Hip Replacement Surgery. Value in Health, 2016, 19, 316-322.	0.3	26
130	Incidence and prognostic factors of chronic pain after isolated musculoskeletal extremity injury. European Journal of Pain, 2016, 20, 711-722.	2.8	21
131	Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 1-13.	0.3	437
132	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 553-561.	2.9	18
133	Organs-on-Chips in Drug Development: The Importance of Involving Stakeholders in Early Health Technology Assessment. Applied in Vitro Toxicology, 2016, 2, 74-81.	1.1	16
134	Ranking medical innovations according to perceived health benefit. Health Policy and Technology, 2016, 5, 156-165.	2.5	5
135	Multiple Criteria Decision Analysis for Health Care Decision Makingâ€"Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 2016, 19, 125-137.	0.3	320
136	Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial. Heart and Vessels, 2016, 31, 1731-1739.	1.2	6
137	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics, 2016, 34, 115-126.	3.3	35
138	Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial. Clinical Research in Cardiology, 2016, 105, 206-215.	3.3	8
139	Involving Patients in Weighting Benefits and Harms of Treatment in Parkinson's Disease. PLoS ONE, 2016, 11, e0160771.	2.5	27
140	Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study. EuroIntervention, 2016, 11, 1487-1494.	3.2	3
141	Interrogating metastatic prostate cancer treatment switch decisions Journal of Clinical Oncology, 2016, 34, 296-296.	1.6	0
142	Building a Bridge Between Clinical Evidence Research and Patient Preference Research. Value in Health, 2015, 18, A554.	0.3	0
143	Trauma team activation varies across Dutch emergency departments: a national survey. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2015, 23, 100.	2.6	10
144	Timed Automata Modeling of The Personalized Treatment Decisions In Metastatic Castration Resistant Prostate Cancer. Value in Health, 2015, 18, A702-A703.	0.3	1

#	Article	IF	CITATIONS
145	Clinical outcome of patients with implantation of secondâ€generation drugâ€eluting stents in the right coronary ostium: Insights from 2â€year followâ€up of the TWENTE trial. Catheterization and Cardiovascular Interventions, 2015, 85, 524-531.	1.7	14
146	2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC). European Journal of Cancer, 2015, 51, S504.	2.8	0
147	Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. BMC Cancer, 2015, 15, 899.	2.6	15
148	Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. BMC Medical Informatics and Decision Making, 2015, 15, 102.	3.0	15
149	Implementation of comparative effectiveness research in personalized medicine applications in oncology: current and future perspectives. Comparative Effectiveness Research, 2015, , 65.	0.2	4
150	Using Geographic Information Systems and Multi-Criteria Decision Analysis to Address Spatially Explicit Problems in Healthcare Policy Decision Making. Value in Health, 2015, 18, A482.	0.3	0
151	A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions. Pharmacoeconomics, 2015, 33, 445-455.	3.3	96
152	Applying Dynamic Simulation Modeling Methods in Health Care Delivery Researchâ€"The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 5-16.	0.3	152
153	Pain Management in the Emergency Chain: The Use and Effectiveness of Pain Management in Patients with Acute Musculoskeletal Pain. Pain Medicine, 2015, 16, 970-984.	1.9	44
154	Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice. BMC Family Practice, 2015, 16, 9.	2.9	10
155	A review of the literature regarding biosimilars: what is the evidence for equivalence?. Value in Health, 2015, 18, A3.	0.3	0
156	Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents. JACC: Cardiovascular Interventions, 2015, 8, 889-899.	2.9	41
157	A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. Journal of Medical Economics, 2015, 18, 944-953.	2.1	47
158	Surface Peroneal Nerve Stimulation in Lower Limb Hemiparesis. American Journal of Physical Medicine and Rehabilitation, 2015, 94, 341-357.	1.4	24
159	Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Researchâ€"Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 147-160.	0.3	109
160	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Research and Treatment, 2015, 152, 627-636.	2.5	48
161	Comparison of Timed Automata with Discrete Event Simulation for Modeling Personalized Treatment Decisions: the Case of Metastatic Castration Resistant Prostate Cancer. Value in Health, 2015, 18, A343-A344.	0.3	0
162	Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval. PLoS ONE, 2015, 10, e0120832.	2.5	39

#	Article	IF	Citations
163	MEDICAL DEVICES EARLY ASSESSMENT METHODS: SYSTEMATIC LITERATURE REVIEW. International Journal of Technology Assessment in Health Care, 2014, 30, 137-146.	0.5	65
164	Helmet therapy in infants with positional skull deformation: randomised controlled trial. BMJ, The, 2014, 348, g2741-g2741.	6.0	148
165	Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?. Pharmacoeconomics, 2014, 32, 1-4.	3.3	52
166	Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): Rationale and study design of the randomized TWENTE III multicenter trial. American Heart Journal, 2014, 167, 445-451.	2.7	29
167	Response to Pediatric Physical Therapy in Infants With Positional Preference and Skull Deformation. Physical Therapy, 2014, 94, 1262-1271.	2.4	14
168	A Systematic Review to Identify the Use of Preference Elicitation Methods in Healthcare Decision Making. Pharmaceutical Medicine, 2014, 28, 175-185.	1.9	42
169	Health Economic Impact of Volume Doubling Time as Biomarker in Lung Cancer Diagnosis. Value in Health, 2014, 17, A655.	0.3	0
170	Primary Treatments for Intermediate-Risk Prostate Cancer: a Cost-Effectiveness and Value-of-Information Analysis. Value in Health, 2014, 17, A323.	0.3	0
171	A Validated Prediction Model and Nomogram for Risk of Recurrence in Early Breast Cancer Patients. Value in Health, 2014, 17, A619-A620.	0.3	1
172	Patient Preferences And Hiv Drugs: What About Uncertainty?. Value in Health, 2014, 17, A565.	0.3	0
173	Budget Impact Analysis of a Return-To-Work Intervention for Cancer Patients Shows Hospitals Bear the Costs, for Society to Enjoy the Benefits. Value in Health, 2014, 17, A624.	0.3	0
174	Combining Headroom and Return on Investment Analysis To Rank Potential Commercial Value of Six Medical Devices in Development. Value in Health, 2014, 17, A443.	0.3	2
175	A Systematic Review To Identify the Use of Preference Elicitation Methods in Health Care Decision Making. Value in Health, 2014, 17, A515-A516.	0.3	18
176	Survival After Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval. Value in Health, 2014, 17, A620.	0.3	0
177	Comparison of the Valuation of Treatment Alternatives in Parkinson's Disease with Best-Worst Scaling, Time Trade-off and Visual Analogue Scales. Value in Health, 2014, 17, A401.	0.3	0
178	Parents' decision for helmet therapy in infants with skull deformation. Child's Nervous System, 2014, 30, 1225-1232.	1.1	7
179	Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development. Applied Health Economics and Health Policy, 2014, 12, 327-334.	2.1	16
180	Group Decision Making with the Analytic Hierarchy Process in Benefit-Risk Assessment: A Tutorial. Patient, 2014, 7, 129-140.	2.7	75

#	Article	IF	CITATIONS
181	Public stated preferences and predicted uptake for genome-based colorectal cancer screening. BMC Medical Informatics and Decision Making, 2014, 14, 18.	3.0	25
182	TCT-588 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in "All-Comer―Patients. Journal of the American College of Cardiology, 2014, 64, 8171.	2.8	1
183	The value of quantitative patient preferences in regulatory benefit-risk assessment. Journal of Market Access & Health Policy, 2014, 2, 22761.	1.5	27
184	Multi Criteria Decision Analysis Methods In Health Care: Current Status, Good Practice And Future Recommendations. Value in Health, 2014, 17, A34.	0.3	3
185	Assessing The Impact Of A Multi-Million Public-Private Partnership For Translational Research: The Centre For Translational Molecular Medicine (Ctmm). Value in Health, 2014, 17, A31.	0.3	1
186	Differential cortical activation during observation and observation-and-imagination. Experimental Brain Research, 2013, 229, 337-345.	1.5	61
187	Evaluating the cost-effectiveness of multicomponent rehabilitation guidelines. Value in Health, 2013, 16, A30.	0.3	0
188	Empirical Comparison Of Discrete Choice Experiment And Best-Worst Scaling To Estimate Stakeholders' Risk Tolerance For Hip Replacement Surgery. Value in Health, 2013, 16, A226-A227.	0.3	2
189	The Expected Value Of Bio-Artificial Pancreas Development In View Of Endocrinologists' And Patients' Preferences. Value in Health, 2013, 16, A169.	0.3	0
190	Structuring Criteria In Multi-Criteria Decision Models For Benefit/Risk Assessment Of Biologics In Juvenile Arthritis. Value in Health, 2013, 16, A219.	0.3	0
191	Cost-Utility of Metal-on-Metal Hip Resurfacing Compared to Conventional Total Hip Replacement in Young Active Patients with Osteoarthritis. Value in Health, 2013, 16, 942-952.	0.3	22
192	The Expected Health Economic Value of Using Circulating Tumor Cells to Personalize Cancer Treatment. Value in Health, 2013, 16, A424.	0.3	0
193	Added Value and Future Adoption of a New Medical Imaging Technology for Interventional Cardiology. Value in Health, 2013, 16, A540.	0.3	0
194	Randomized Controlled Trial of Surface Peroneal Nerve Stimulation for Motor Relearning in Lower Limb Hemiparesis. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1007-1014.	0.9	52
195	Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis. Applied Health Economics and Health Policy, 2013, 11, 499-507.	2.1	25
196	Breast cancer follow-up: from the perspective of health professionals and patients. European Journal of Cancer Care, 2013, 22, 754-764.	1.5	22
197	Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes. British Journal of Cancer, 2013, 109, 866-871.	6.4	14
198	Psychosocial predictors of parental participation in ultrasound screening for developmental dysplasia of the hip Families, Systems and Health, 2013, 31, 218-229.	0.6	3

#	Article	IF	CITATIONS
199	Determinants of parental satisfaction with ultrasound hip screening in child health care. Journal of Child Health Care, 2012, 16, 178-189.	1.4	4
200	Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review. Oncologist, 2012, 17, 1581-1593.	3.7	109
201	Changes in muscle activation after reach training with gravity compensation in chronic stroke patients. International Journal of Rehabilitation Research, 2012, 35, 234-242.	1.3	15
202	RE. American Journal of Physical Medicine and Rehabilitation, 2012, 91, 279-280.	1.4	2
203	PRM79 Integrating Patient Preferences and Clinical Trial Data in a Bayesian Model for Quantitative Risk-Benefit Assessment. Value in Health, 2012, 15, A474.	0.3	2
204	A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation. Patient, 2012, 5, 45-56.	2.7	52
205	Using the Analytic Hierarchy Process to Elicit Patient Preferences. Patient, 2012, 5, 225-237.	2.7	52
206	Predicting Participation in Ultrasound Hip Screening From Message Framing. Health Communication, 2012, 27, 186-193.	3.1	7
207	HElmet therapy Assessment in infants with Deformed Skulls (HEADS): protocol for a randomised controlled trial. Trials, 2012, 13, 108.	1.6	18
208	Multimodal and Widespread Somatosensory Abnormalities in Persistent Shoulder Pain in the First 6 Months After Stroke: An Exploratory Study. Archives of Physical Medicine and Rehabilitation, 2012, 93, 1968-1974.	0.9	30
209	PMS57 Towards Patient-Centered Telemedicine Design: Estimating Patients' Preferences of Telemedicine Exercise Services Using a Conjoint Experiment. Value in Health, 2012, 15, A44.	0.3	0
210	PMD72 The Use of Multi-Criteria Decision Analysis to Elicit Colorectal Cancer Screening Preferences. Value in Health, 2012, 15, A357-A358.	0.3	0
211	PMD80 Preferences for a New Imaging Technique to Detect Breast Cancer. Value in Health, 2012, 15, A359.	0.3	0
212	PMD91 Scenario Analysis and Real Options Modeling of Home Brain Monitoring in Epilepsy Patients. Value in Health, 2012, 15, A361.	0.3	0
213	PRM166 The Challenge of Assessing Health Technologies Early in the Development. Systematic Literature Review of Methods in Use. Value in Health, 2012, 15, A491.	0.3	0
214	Predicting the health economic performance of new nonâ€fusion surgery in adolescent idiopathic scoliosis. Journal of Orthopaedic Research, 2012, 30, 1453-1458.	2.3	12
215	Early Bayesian modeling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk of hyperkalaemia. Technological Forecasting and Social Change, 2012, 79, 1268-1279.	11.6	5
216	An exploration of chronic pain patients' perceptions of home telerehabilitation services. Health Expectations, 2012, 15, 339-350.	2.6	95

#	Article	IF	Citations
217	Using the Analytic Hierarchy Process to Elicit Patient Preferences. Patient, 2012, 5, 225-237.	2.7	25
218	PRM18 Sensitivity Analysis in Multi-Criteria Decision (MCDA) Models for Benefit-Risk Assessment. Value in Health, 2011, 14, A424.	0.3	0
219	CN2 Measuring Public Preferences For Colorectal Cancer Screening Using New Genome-Based Nanotechnologies. Value in Health, 2011, 14, A234.	0.3	0
220	PMD78 Benefit-Risk Analysis in Absence of Clinical Evidence: Deciding for Treatment of Skull Deformity in Babies Aged 5 Months. Value in Health, 2011, 14, A258.	0.3	0
221	Early Assessment of Medical Technologies to Inform Product Development and Market Access. Applied Health Economics and Health Policy, 2011, 9, 331-347.	2.1	136
222	Persistent Shoulder Pain in the First 6 Months After Stroke: Results of a Prospective Cohort Study. Archives of Physical Medicine and Rehabilitation, 2011, 92, 1139-1145.	0.9	60
223	Early cardiopulmonary resuscitation and use of Automated External Defibrillators by laypersons in out-of-hospital cardiac arrest using an SMS alert service. Resuscitation, 2011, 82, 1273-1278.	3.0	45
224	Somatosensory Symptoms and Signs and Conditioned Pain Modulation in Chronic Post-Stroke Shoulder Pain. Journal of Pain, 2011, 12, 476-485.	1.4	66
225	Long-term administration of fluoxetine to improve motor recovery after stroke. Future Neurology, 2011, 6, 455-457.	0.5	1
226	Altered cortical somatosensory processing in chronic stroke: A relationship with post-stroke shoulder pain. NeuroRehabilitation, 2011, 28, 331-344.	1.3	29
227	Patient preferences for next generation neural prostheses to restore bladder function. Spinal Cord, 2011, 49, 113-119.	1.9	23
228	Classifying post-stroke shoulder pain: Can the DN4 be helpful?. European Journal of Pain, 2011, 15, 99-102.	2.8	14
229	Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis. Medical Devices: Evidence and Research, 2011, 4, 107.	0.8	24
230	Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences. International Journal of Technology Assessment in Health Care, 2011, 27, 369-375.	0.5	142
231	Change of Patients' Perceptions of Telemedicine After Brief Use. Telemedicine Journal and E-Health, 2011, 17, 530-535.	2.8	66
232	Towards a mechanism-based view on post-stroke shoulder pain: Theoretical considerations and clinical implications. NeuroRehabilitation, 2010, 30, 153-165.	1.3	23
233	Defining post-stroke pain: diagnostic challenges. Lancet Neurology, The, 2010, 9, 344.	10.2	15
234	An explorative, cross-sectional study into abnormal muscular coupling during reach in chronic stroke patients. Journal of NeuroEngineering and Rehabilitation, 2010, 7, 14.	4.6	11

#	Article	IF	CITATIONS
235	Measuring Quality of Life in Stroke Subjects Receiving an Implanted Neural Prosthesis for Drop Foot. Artificial Organs, 2010, 34, 366-376.	1.9	14
236	Effects of dynamic sitting interventions on tissue oxygenation in individuals with spinal cord disorders. Spinal Cord, 2010, 48, 336-341.	1.9	12
237	The potential for shared decision-making and decision aids in rehabilitation medicine. Journal of Rehabilitation Medicine, 2010, 42, 598-604.	1.1	26
238	Feasibility of web-based decision aids in neurological patients. Journal of Telemedicine and Telecare, 2010, 16, 48-52.	2.7	14
239	Single Dose of Fluoxetine Increases Muscle Activation in Chronic Stroke Patients. Clinical Neuropharmacology, 2009, 32, 1-5.	0.7	19
240	Influence of Gravity Compensation on Muscle Activation Patterns During Different Temporal Phases of Arm Movements of Stroke Patients. Neurorehabilitation and Neural Repair, 2009, 23, 478-485.	2.9	76
241	120 CENTRAL NEUROPATHIC MECHANISMS IN POSTâ€STROKE SHOULDER PAIN. European Journal of Pain, 2009, 13, S44.	2.8	3
242	The effect of information on preferences stated in a choice-based conjoint analysis. Patient Education and Counseling, 2009, 74, 264-271.	2.2	22
243	Clinical Use of Interface Pressure to Predict Pressure Ulcer Development: A Systematic Review. Assistive Technology, 2009, 21, 76-85.	2.0	59
244	Influence of gravity compensation on muscle activity during reach and retrieval in healthy elderly. Journal of Electromyography and Kinesiology, 2009, 19, e40-e49.	1.7	49
245	Neuromuscular stimulation after stroke: from technology to clinical deployment. Expert Review of Neurotherapeutics, 2009, 9, 541-552.	2.8	14
246	PP1 A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING. Value in Health, 2009, 12, A227.	0.3	13
247	PHP47 EARLY ASSESSMENT OF HIGHLY INNOVATIVE MEDICAL TECHNOLOGY: CLINICAL AND ECONOMICAL GAINS OF POINT-OF-CARE APPLICATIONS FOR MEASURING POTASSIUM CONCENTRATIONS. Value in Health, 2009, 12, A246.	0.3	O
248	PIH43 EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS. Value in Health, 2009, 12, A298.	0.3	0
249	PIN75 ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON THE MALARIA CONTROL PROGRAM IN BRAZIL. Value in Health, 2009, 12, A431.	0.3	O
250	Analysis of healthy sitting behavior: Interface pressure distribution and subcutaneous tissue oxygenation. Journal of Rehabilitation Research and Development, 2009, 46, 577.	1.6	60
251	Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clinical Neuropharmacology, 2009, 32, 1-5.	0.7	25
252	Decision for reconstructive interventions of the upper limb in individuals with tetraplegia: the effect of treatment characteristics. Spinal Cord, 2008, 46, 228-233.	1.9	18

#	Article	IF	CITATIONS
253	PHP4 PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER. Value in Health, 2008, 11, A363.	0.3	0
254	PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE. Value in Health, 2008, 11, A411.	0.3	0
255	PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER. Value in Health, 2008, 11, A489-A490.	0.3	0
256	Recovery of Gait After Stroke: What Changes?. Neurorehabilitation and Neural Repair, 2008, 22, 676-683.	2.9	113
257	The Use of the Analytic Hierarchy Process to Aid Decision Making in Acquired Equinovarus Deformity. Archives of Physical Medicine and Rehabilitation, 2008, 89, 457-462.	0.9	39
258	The Use of Multi-Criteria Decision Analysis Weight Elicitation Techniques in Patients with MildÂCognitive Impairment. Patient, 2008, 1, 127-135.	2.7	21
259	Therapeutic Effect of an Implantable Peroneal Nerve Stimulator in Subjects With Chronic Stroke and Footdrop: A Randomized Controlled Trial. Physical Therapy, 2008, 88, 437-448.	2.4	77
260	A Low-Cost Video Game Applied for Training of Upper Extremity Function in Children with Cerebral Palsy: A Pilot Study. Cyberpsychology, Behavior and Social Networking, 2008, 11, 27-32.	2.2	130
261	Comparison of Two Multi-Criteria Decision Techniques for Eliciting Treatment Preferences in People withANeurological Disorders. Patient, 2008, 1, 265-272.	2.7	40
262	Electrical stimulation of the upper extremity in stroke: cyclic versus EMG-triggered stimulation. Clinical Rehabilitation, 2008, 22, 690-697.	2.2	73
263	Rehabilitation outcome of upper extremity skilled performance in persons with cervical spinal cord injuries. Journal of Rehabilitation Medicine, 2008, 40, 637-644.	1.1	20
264	Increased range of motion and decreased muscle activity during maximal reach with gravity compensation in stroke patients. , 2007, , .		15
265	Reduction of muscle activity during repeated reach and retrieval with gravity compensation in stroke patients., 2007,,.		7
266	Virtual reality for mobility devices: training applications and clinical results: a review. International Journal of Rehabilitation Research, 2007, 30, 91-96.	1.3	42
267	A Randomized Controlled Trial of an Implantable 2-Channel Peroneal Nerve Stimulator on Walking Speed and Activity in Poststroke Hemiplegia. Archives of Physical Medicine and Rehabilitation, 2007, 88, 971-978.	0.9	135
268	Cross-diagnostic validity of the SF-36 physical functioning scale in patients with stroke, multiple sclerosis and amyotrophic lateral sclerosis: A study using rasch analysis. Acta Dermato-Venereologica, 2007, 39, 163-169.	1.3	26
269	A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain. Disability and Rehabilitation, 2006, 28, 645-651.	1.8	19
270	Effectiveness of Custom-Made Orthopaedic Shoes in the Reduction of Foot Pain and Pressure in Patients with Degenerative Disorders of the Foot. Foot and Ankle International, 2006, 27, 974-979.	2.3	34

#	Article	IF	CITATIONS
271	Comparison of Electric Stimulation Methods for Reduction of Triceps Surae Spasticity in Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2006, 87, 222-228.	0.9	47
272	The Effect of Fear of Movement on Muscle Activation in Posttraumatic Neck Pain Disability. Clinical Journal of Pain, 2006, 22, 519-525.	1.9	56
273	Effect of Electrical Stimulation of Hamstrings and L3/4 Dermatome on Gait in Spinal Cord Injury. Neuromodulation, 2006, 9, 48-55.	0.8	3
274	Measurement properties of the short version of the Van Lieshout test for arm/hand function of persons with tetraplegia after spinal cord injury. Spinal Cord, 2006, 44, 763-771.	1.9	51
275	Systematic review of the effect of robot-aided therapy on recovery of the hemiparetic arm after stroke. Journal of Rehabilitation Research and Development, 2006, 43, 171.	1.6	782
276	A Systematic Review of Sociodemographic, Physical, and Psychological Predictors of Multidisciplinary Rehabilitationâ€"or, Back School Treatment Outcome in Patients With Chronic Low Back Pain. Spine, 2005, 30, 813-825.	2.0	119
277	Gait Impairments in a Group of Patients With Incomplete Spinal Cord Injury and Their Relevance Regarding Therapeutic Approaches Using Functional Electrical Stimulation. Artificial Organs, 2005, 29, 8-14.	1.9	50
278	Early treatment of trans-tibial amputees. Prosthetics and Orthotics International, 2005, 29, 3-12.	1.0	38
279	Differential item functioning of the functional independence measure in higher performing neurological patients. Journal of Rehabilitation Medicine, 2005, 37, 346-352.	1.1	36
280	RELATION BETWEEN STIMULATION CHARACTERISTICS AND CLINICAL OUTCOME IN STUDIES USING ELECTRICAL STIMULATION TO IMPROVE MOTOR CONTROL OF THE UPPER EXTREMITY IN STROKE. Journal of Rehabilitation Medicine, 2005, 37, 65-74.	1.1	224
281	Preferences of general practitioners regarding an application running on a personal digital assistant in acute stroke care. Journal of Telemedicine and Telecare, 2005, 11, 37-39.	2.7	15
282	PNL15 PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE UPPER EXTREMITIES IN TETRAPLEGIA: THE IMPACT OF TREATMENT CHARACTERISTICS. Value in Health, 2005, 8, A132-A133.	0.3	0
283	Use of orthopedic shoes in patients with degenerative disorders of the foot. Archives of Physical Medicine and Rehabilitation, 2005, 86, 687-692.	0.9	21
284	Choice-Based Evaluation for the Improvement of Upper-Extremity Function Compared With Other Impairments in Tetraplegia. Archives of Physical Medicine and Rehabilitation, 2005, 86, 1623-1630.	0.9	30
285	Development of a New Method for Objective Assessment of Spasticity Using Full Range Passive Movements. Archives of Physical Medicine and Rehabilitation, 2005, 86, 1991-1997.	0.9	18
286	A multicriteria decision analysis of augmentative treatment of upper limbs in persons with tetraplegia. Journal of Rehabilitation Research and Development, 2005, 42, 635.	1.6	36
287	Economic evaluation of neuro-prostheses: A review of outcome assessment and valuation techniques. Technology and Disability, 2004, 16, 33-40.	0.6	1
288	Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of life. Clinical Rehabilitation, 2004, 18, 359-365.	2.2	87

#	Article	IF	CITATIONS
289	Differences in outcome of a multidisciplinary treatment between subgroups of chronic low back pain patients defined using two multiaxial assessment instruments: the Multidimensional Pain Inventory and lumbar dynamometry. Clinical Rehabilitation, 2004, 18, 566-579.	2.2	57
290	The effect of an ankle-foot orthosis on walking ability in chronic stroke patients: a randomized controlled trial. Clinical Rehabilitation, 2004, 18, 550-557.	2.2	145
291	The Orthotic Effect of Functional Electrical Stimulation on the Improvement of Walking in Stroke Patients with a Dropped Foot: A Systematic Review. Artificial Organs, 2004, 28, 577-586.	1.9	203
292	Survey of the needs of patients with spinal cord injury: impact and priority for improvement in hand function in tetraplegics. Spinal Cord, 2004, 42, 526-532.	1.9	462
293	Predictive value of fear avoidance in developing chronic neck pain disability: consequences for clinical decision making. Archives of Physical Medicine and Rehabilitation, 2004, 85, 496-501.	0.9	189
294	Electrical Stimulation of the Upper Limb in Stroke. American Journal of Physical Medicine and Rehabilitation, 2004, 83, 592-600.	1.4	43
295	A 7-year follow-up of sacral anterior root stimulation for bladder control in patients with a spinal cord injury: quality of life and users' experiences. Spinal Cord, 2003, 41, 397-402.	1.9	71
296	Chronic neck pain disability due to an acute whiplash injury. Pain, 2003, 102, 63-71.	4.2	85
297	PRE-ASSESSMENT TO ASSESS THE MATCH BETWEEN COST-EFFECTIVENESS RESULTS AND DECISION MAKERS' INFORMATION NEEDS. International Journal of Technology Assessment in Health Care, 2003, 19, 17-27.	0.5	13
298	Cervical Muscle Dysfunction in Chronic Whiplash-Associated Disorder Grade 2. Spine, 2002, 27, 1056-1061.	2.0	97
299	The Come Back Programme: a rehabilitation programme for patients with brain injury with psychosocial problems despite previous rehabilitation. International Journal of Rehabilitation Research, 2002, 25, 271-278.	1.3	11
300	Therapeutic electrical stimulation to improve motor control and functional abilities of the upper extremity after stroke: a systematic review. Clinical Rehabilitation, 2002, 16, 350-360.	2.2	180
301	Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Archives of Physical Medicine and Rehabilitation, 2002, 83, 1777-1782.	0.9	63
302	Functional electrical stimulation by means of the â€~Ness Handmaster Orthosis' in chronic stroke patients: an exploratory study. Clinical Rehabilitation, 2001, 15, 217-220.	2.2	58
303	Cervical Muscle Dysfunction in the Chronic Whiplash Associated Disorder Grade II (WAD-II). Spine, 2000, 25, 1938-1943.	2.0	144
304	Use of the NESS Handmaster to restore handfunction in tetraplegia: clinical experiences in ten patients. Spinal Cord, 2000, 38, 244-249.	1.9	100
305	Validity and reproducibility of crutch force and heart rate measurements to assess energy expenditure of paraplegic gait. Archives of Physical Medicine and Rehabilitation, 1999, 80, 1017-1023.	0.9	51
306	Speed dependence of crutch force and oxygen uptake: Implications for design of comparative trials on orthoses for people with paraplegia. Archives of Physical Medicine and Rehabilitation, 1998, 79, 1408-1414.	0.9	6

#	Article	IF	CITATIONS
307	The influence of the reciprocal cable linkage in the advanced reciprocating gait orthosis on paraplegic gait performance. Prosthetics and Orthotics International, 1997, 21, 52-61.	1.0	38
308	The influence of the reciprocal hip joint link in the Advanced Reciprocating Gait Orthosis on standing performance in paraplegia. Prosthetics and Orthotics International, 1997, 21, 210-221.	1.0	31
309	The influence of voluntary upper body exercise on the performance of stimulated paralysed human quadriceps. Journal of Electromyography and Kinesiology, 1997, 7, 67-77.	1.7	5
310	Global burden of lung cancer: implications from current evidence. Annals of Cancer Epidemiology, 0, 5, 4-4.	1.8	5